Document is current
Any future updates will be listed below
-
Authors
Arce, Maya M.
Umhoefer, Jennifer M. https://orcid.org/0000-0002-8563-9641
Arang, Nadia
Kasinathan, Sivakanthan https://orcid.org/0000-0003-2218-6371
Freimer, Jacob W. https://orcid.org/0000-0001-9239-2272
Steinhart, Zachary
Shen, Haolin https://orcid.org/0000-0003-1550-2831
Pham, Minh T. N.
Ota, Mineto https://orcid.org/0000-0003-4552-8573
Wadhera, Anika https://orcid.org/0009-0009-4694-6129
Dajani, Rama
Dorovskyi, Dmytro https://orcid.org/0009-0007-4297-2958
Chen, Yan Yi
Liu, Qi
Zhou, Yuan https://orcid.org/0000-0002-1393-5476
Swaney, Danielle L. https://orcid.org/0000-0001-6119-6084
Obernier, Kirsten https://orcid.org/0000-0002-4025-1299
Shy, Brian R. https://orcid.org/0000-0001-9569-3708
Carnevale, Julia https://orcid.org/0000-0001-9410-7148
Satpathy, Ansuman T. https://orcid.org/0000-0002-5167-537X
Krogan, Nevan J. https://orcid.org/0000-0003-4902-337X
Pritchard, Jonathan K. https://orcid.org/0000-0002-8828-5236
Marson, Alexander
- License Information
-
More Information
Article History
Received: 5 October 2023
Accepted: 30 October 2024
First Online: 11 December 2024
Competing interests
: A.M. is a cofounder of Site Tx, Arsenal Biosciences, Spotlight Therapeutics and Survey Genomics; serves on the boards of directors at Site Tx, Spotlight Therapeutics and Survey Genomics; is a member of the scientific advisory boards of Site Tx, Arsenal Biosciences, Cellanome, Spotlight Therapeutics, Survey Genomics, NewLimit, Amgen and Tenaya; owns stock in Arsenal Biosciences, Site Tx, Cellanome, Spotlight Therapeutics, NewLimit, Survey Genomics, Tenaya and Lightcast; has received fees from Site Tx, Arsenal Biosciences, Cellanome, Spotlight Therapeutics, NewLimit, Gilead, Pfizer, 23andMe, PACT Pharma, Juno Therapeutics, Tenaya, Lightcast, Trizell, Vertex, Merck, Amgen, Genentech, GLG, ClearView Healthcare, AlphaSights, Rupert Case Management, Bernstein and ALDA; is an investor in and informal advisor to Offline Ventures; and a client of EPIQ. The Marson laboratory has received research support from the Parker Institute for Cancer Immunotherapy, the Emerson Collective, Arc Institute, Juno Therapeutics, Epinomics, Sanofi, GlaxoSmithKline, Gilead and Anthem and reagents from Genscript and Illumina. The Krogan Laboratory has received research support from Vir Biotechnology, F. Hoffmann-La Roche and Rezo Therapeutics. N.J.K. has a financially compensated consulting agreement with Maze Therapeutics. N.J.K. is the President and on the Board of Directors of Rezo Therapeutics; and is a shareholder in Tenaya Therapeutics, Maze Therapeutics, Rezo Therapeutics, GEn1E Lifesciences and Interline Therapeutics. J.W.F. was a consultant for NewLimit; is an employee of Genentech; and has equity in Roche. A.T.S. is a founder of Immunai, Cartography Biosciences, Santa Ana Bio and Prox Biosciences; is an advisor to Zafrens and Wing Venture Capital; and receives research funding from Astellas and Merck Research Laboratories. Patent applications have been filed based on the findings described here. The other authors declare no competing interests.
